FDA Drug Safety Cmte. Includes Two Specialists In Medication Mix-Ups
This article was originally published in The Tan Sheet
Executive Summary
FDA's risk management subcommittee member Michael Cohen is a pioneer in treating medication errors as systemic, correctable events that should be addressed as part of the drug review process
You may also be interested in...
FDA Drug Safety Office Losing Honig, But Gaining FTEs
FDA is looking for a new director for its fledgling Office of Drug Safety following the departure of Peter Honig, MD, to Merck
Drug Risk Management Advisory Panel To Be Formed Under Pharm. Science
FDA's planned drug risk management advisory committee will be formed as a subcommittee of the Center for Drug Evaluation & Research's Advisory Committee for Pharmaceutical Science
Brand Name Confusion Preventable Under Existing Regs, Industry Rep Says
Established brand history and OTC labeling rules provide consumers with enough information to avoid confusing self-care products carrying similar brand names and different active ingredients, Consumer Healthcare Products Association General Counsel Eve Bachrach told an FDA panel June 28.